Eliezer Jesus de Lacerda Barreiro

List of Publications by Year
in descending order

278 papers	9,975 citations	53794 45 h-index	45317 90 g-index

294 all docs	294 docs citations	294 times ranked	12179 citing authors

#	Article	IF	Citations
1	Molecular Hybridization: A Useful Tool in the Design of New Drug Prototypes. Current Medicinal Chemistry, 2007, 14, 1829-1852.	2.4	930
2	The Methylation Effect in Medicinal Chemistry. Chemical Reviews, 2011, 111, 5215-5246.	47.7	671
3	Bioisosterism: A Useful Strategy for Molecular Modification and Drug Design. Current Medicinal Chemistry, 2005, 12, 23-49.	2.4	563
4	From Nature to Drug Discovery: The Indole Scaffold as a ‘Privileged Structure’. Mini-Reviews in Medicinal Chemistry, 2009, 9, 782-793.	2.4	498
5	Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?. Journal of Medicinal Chemistry, 2018, 61, 5805-5821.	6.4	343
6	Privileged Structures: A Useful Concept for the Rational Design of New Lead Drug Candidates. Mini-Reviews in Medicinal Chemistry, 2007, 7, 1108-1119.	2.4	266
7	Î²-lactam antibiotics: An overview from a medicinal chemistry perspective. European Journal of Medicinal Chemistry, 2020, 208, 112829.	5.5	227
8	Synthesis and analgesic activity of novel N-acylarylhydrazones and isosters, derived from natural safrole##This paper represents contribution # 36 of the LASSBio, UFRJ (Br.) (LASSBio,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 462 Td (htt Chemistry, 2000, 35, 187-203.	5.5	195
9	Synthesis and evaluation of analgesic, antiinflammatory and antiplatelet properties of new 2-pyridylarylhydrazone derivatives. European Journal of Medicinal Chemistry, 1998, 33, 189-199.	5.5	188
10	Discovery of novel analgesic and anti-inflammatory 3-arylamine-imidazo[1,2-a]pyridine symbiotic prototypes. Bioorganic and Medicinal Chemistry, 2009, 17, 74-84.	3.0	187
11	Synthesis and anti-inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues. Bioorganic and Medicinal Chemistry, 2002, 10, 3067-3073.	3.0	174
12	Antiplatelet properties of novel N-substituted-phenyl-1,2,3-triazole-4-acylhydrazone derivatives. Bioorganic and Medicinal Chemistry, 2003, 11, 2051-2059.	3.0	168
13	N-Acylhydrazones as drugs. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2797-2806.	2.2	140
14	New class of potent antinociceptive and antiplatelet 10H-phenothiazine-1-acylhydrazone derivatives. Bioorganic and Medicinal Chemistry, 2004, 12, 3149-3158.	3.0	125
15	Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors. European Journal of Medicinal Chemistry, 2014, 71, 1-14.	5.5	109
16	Design, Synthesis, and Pharmacological Evaluation of N-Acylhydrazones and Novel Conformationally Constrained Compounds as Selective and Potent Orally Active Phosphodiesterase-4 Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 7525-7545.	6.4	105
17	Further Bioactive Piperidine Alkaloids from the Flowers and Green Fruits ofCassiaspectabilis. Journal of Natural Products, 2004, 67, 908-910.	3.0	104
18	Design, Synthesis, and Pharmacological Profile of Novel Fused Pyrazolo[4,3-d]pyridine and Pyrazolo[3,4-b][1,8]naphthyridine Isosteres:Â A New Class of Potent and Selective Acetylcholinesterase Inhibitors. Journal of Medicinal Chemistry, 2003, 46, 1144-1152.	6.4	101

#	Article	IF	Citations
19	Medicinal Chemistry of N-Acylhydrazones: New Lead-Compounds of Analgesic, Antiinflammatory and Antithrombotic Drugs. Current Medicinal Chemistry, 2006, 13, 167-198.	2.4	95
20	Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates. Bioorganic and Medicinal Chemistry, 2009, 17, 641-652.	3.0	94
21	Os produtos naturais e a quÃmica medicinal moderna. Quimica Nova, 2006, 29, 326-337.	0.3	93
22	The Role of Natural Products in the Discovery of New Drug Candidates for the Treatment of Neurodegenerative Disorders II: Alzheimers Disease. CNS and Neurological Disorders - Drug Targets, 2011, 10, 251-270.	1.4	93
23	Synthesis and vasodilatory activity of new N-acylhydrazone derivatives, designed as LASSBio-294 analogues. Bioorganic and Medicinal Chemistry, 2005, 13, 3431-3437.	3.0	87
24	Characterization of Amide Bond Conformers for a Novel Heterocyclic Template of N-acylhydrazone Derivatives. Molecules, 2013, 18, 11683-11704.	3.8	82
25	Design and synthesis of 3,4-methylenedioxy-6-nitrophenoxyacetylhydrazone derivatives obtained from natural safrole: New lead-agents with analgesic and antipyretic properties. Bioorganic and Medicinal Chemistry, 2006, 14, 7924-7935.	3.0	80
26	Structureâ^'Activity Relationships of the Antimalarial Agent Artemisinin. 6. The Development of Predictive In Vitro Potency Models Using CoMFA and HQSAR Methodologies. Journal of Medicinal Chemistry, 2002, 45, 292-303.	6.4	78
27	Studies towards the identification of putative bioactive conformation of potent vasodilator arylidene N-acylhydrazone derivatives. European Journal of Medicinal Chemistry, 2009, 44, 4004-4009.	5.5	71
28	Design, synthesis and antiinflammatory activity of novel phthalimide derivatives, structurally related to thalidomide. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1169-1172.	2.2	70
29	Design, synthesis and pharmacological profile of novel dopamine D2 receptor ligands. Bioorganic and Medicinal Chemistry, 2003, 11, 4807-4813.	3.0	67
30	Flavonols from Pterogyne nitens and their evaluation as myeloperoxidase inhibitors. Phytochemistry, 2008, 69, 1739-1744.	2.9	67
31	2-Acetylpyridine thiosemicarbazones: Cytotoxic activity in nanomolar doses against malignant gliomas. European Journal of Medicinal Chemistry, 2010, 45, 5671-5677.	5.5	63
32	Discovery of new orally effective analgesic and anti-inflammatory hybrid furoxanyl N-acylhydrazone derivatives. Bioorganic and Medicinal Chemistry, 2012, 20, 2158-2171.	3.0	62
33	Synthesis and antinociceptive properties of new structurally planned imidazo[1,2-a]pyridine 3-acylarylhydrazone derivatives. European Journal of Medicinal Chemistry, 1998, 33, 225-235.	5.5	61
34	Synthesis and anti-platelet activity of novel arylsulfonateâ€“acylhydrazone derivatives, designed as antithrombotic candidates. European Journal of Medicinal Chemistry, 2008, 43, 348-356.	5.5	60
35	Synthesis, pharmacological evaluation and electrochemical studies of novel 6-nitro-3,4-methylenedioxyphenyl-N-acylhydrazone derivatives: Discovery of LASSBio-881, a new ligand of cannabinoid receptors. Bioorganic and Medicinal Chemistry, 2007, 15, 2421-2433.	3.0	59
36	Searching for multi-target antipsychotics: Discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors. Bioorganic and Medicinal Chemistry, 2010, 18, 1925-1935.	3.0	57

#	Article	IF	Citations
37	Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates. European Journal of Medicinal Chemistry, 2013, 59, 64-74.	5.5	57
38	New oxidovanadium(IV) N -acylhydrazone complexes: Promising antileishmanial and antitrypanosomal agents. European Journal of Medicinal Chemistry, 2013, 62, 20-27.	5.5	57
39	Synthesis and pharmacological evaluation of pyrazine N-acylhydrazone derivatives designed as novel analgesic and anti-inflammatory drug candidates. Bioorganic and Medicinal Chemistry, 2010, 18, 5007-5015.	3.0	53
40	Biodiversidade: fonte potencial para a descoberta de fÃ¡rmacos. Quimica Nova, 2009, 32, 679-688.	0.3	51
41	A novel 3D-QSAR comparative molecular field analysis (CoMFA) model of imidazole and quinazolinone functionalized p38 MAP kinase inhibitors. Bioorganic and Medicinal Chemistry, 2004, 12, 3159-3166.	3.0	50
42	Docking, Synthesis and Antiproliferative Activity of N-Acylhydrazone Derivatives Designed as Combretastatin A4 Analogues. PLoS ONE, 2014, 9, e85380.	2.5	50
43	New selective acetylcholinesterase inhibitors designed from natural piperidine alkaloids. Bioorganic and Medicinal Chemistry, 2005, 13, 4184-4190.	3.0	48
44	Design, synthesis and analgesic properties of novel conformationally-restricted N-acylhydrazones (NAH). Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4963-4966.	2.2	48
45	Analgesic and Anti-Inflammatory Activities of Salicylaldehyde 2-Chlorobenzoyl Hydrazone (H2LASSBio-466), Salicylaldehyde 4-Chlorobenzoyl Hydrazone (H2LASSBio-1064) and Their Zinc(II) Complexes. Molecules, 2011, 16, 6902-6915.	3.8	48
46	Design and Synthesis of Novel Potent Antinociceptive Agents: Methyl-imidazolyl N-Acylhydrazone Derivatives. Bioorganic and Medicinal Chemistry, 2000, 8, 2243-2248.	3.0	47
47	A quÃmica medicinal de N-acilidrazonas: novos compostos-protÃ³tipos de fÃ¡rmacos analgÃ©sicos, antiinflamatÃ³rios e anti-trombÃ³ticos. Quimica Nova, 2002, 25, 129-148.	0.3	42
48	Design, synthesis, and pharmacological evaluation of new neuroactive pyrazolo[3,4-b]pyrrolo[3,4-d]pyridine derivatives with in vivo hypnotic and analgesic profile. Bioorganic and Medicinal Chemistry, 2006, 14, 632-640.	3.0	41
49	Synthesis and analgesic properties of 5-acyl-arylhydrazone 1-H pyrazolo [3,4-b] pyridine derivatives. Pharmaceutica Acta Helvetiae, 1994, 69, 163-169.	1.2	40
50	Cytotoxic Guanidine Alkaloids from Pterogyne nitens. Journal of Natural Products, 2009, 72, 473-476.	3.0	40
51	Synthesis and analgesic properties of new 4-arylhydrazone 1-H pyrazole [3,4-b] pyridine derivatives. Pharmaceutica Acta Helvetiae, 1996, 71, 213-219.	1.2	39
52	New Anti-Alzheimer Drugs from Biodiversity: The Role of the Natural Acetylcholinesterase Inhibitors. Mini-Reviews in Medicinal Chemistry, 2005, 5, 915-926.	2.4	39
53	Microwave-assisted synthesis and structureâ€“activity relationships of neuroactive pyrazolo[3,4-b]pyrrolo[3,4-d]pyridine derivatives. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 74-77.	2.2	39
54	Binuclear zinc(II) complexes with the anti-inflammatory compounds salicylaldehyde semicarbazone and salicylaldehyde-4-chlorobenzoyl hydrazone (H2LASSBio-1064). Polyhedron, 2011, 30, 1891-1898.	2.2	39

#	Article	IF	Citations
55	Novel Orally Active Analgesic and Anti-Inflammatory Cyclohexyl-N-Acylhydrazone Derivatives. Molecules, 2015, 20, 3067-3088.	3.8	39
56	Synthesis and pharmacological evaluation of novel heterotricyclic acylhydrazone derivatives, designed as PAF antagonists. European Journal of Pharmaceutical Sciences, 2000, 11, 285-290.	4.0	37
57	New isoxazole derivatives designed as nicotinic acetylcholine receptor ligand candidates. European Journal of Medicinal Chemistry, 2002, 37, 163-170.	5.5	37
58	Beneficial effects of a novel agonist of the adenosine <scp>A_{2A}</scp> receptor on monocrotalineâ€induced pulmonary hypertension in rats. British Journal of Pharmacology, 2013, 169, 953-962.	5.4	37
59	A utilizaÃ§Ã£o do safrol, principal componente quÃmico do Ã³leo de sassafrÃ¡z, na sÃntese de substÃ¢ncias bioativas na cascata do Ã¡cido araquidÃ´nico: antiinflamatÃ³rios, analgÃ©sicos e anti-trombÃ³ticos. Quimica Nova, 1999, 22, 744-759.	0.3	37
60	New potent 5-substituted benzofuroxans as inhibitors of Trypanosoma cruzi growth: Quantitative structureâ€“activity relationship studies. Bioorganic and Medicinal Chemistry, 2005, 13, 6336-6346.	3.0	36
61	Antihypertensive profile of 2-thienyl-3,4-methylenedioxybenzoylhydrazone isÂmediated by activation of the A2A adenosine receptor. European Journal of Medicinal Chemistry, 2012, 55, 49-57.	5.5	36
62	N-acylhydrazone derivative ameliorates monocrotaline-induced pulmonary hypertension through the modulation of adenosine AA2R activity. International Journal of Cardiology, 2014, 173, 154-162.	1.7	36
63	Novel 6-methanesulfonamide-3,4-methylenedioxyphenyl-N-acylhydrazones: Orally effective anti-inflammatory drug candidates. Bioorganic and Medicinal Chemistry, 2009, 17, 1125-1131.	3.0	35
64	CNS-selective noncompetitive cholinesterase inhibitors derived from the natural piperidine alkaloid (â^')-spectaline. European Journal of Pharmacology, 2008, 580, 339-349.	3.5	34
65	EstratÃ©gia de simplificaÃ§Ã£o molecular no planejamento racional de fÃ¡rmacos: a descoberta de novo agente cardioativo. Quimica Nova, 2002, 25, 1172-1180.	0.3	33
66	Pharmacokinetic evaluation of LASSBio-579: an N-phenylpiperazine antipsychotic prototype. Journal of Pharmacy and Pharmacology, 2010, 60, 699-707.	2.4	33
67	Synthesis, characterization, DNA binding, DNA cleavage, protein binding and cytotoxic activities of Ru(II) complexes. International Journal of Biological Macromolecules, 2016, 82, 663-670.	7.5	33
68	Discovery of LASSBio-772, a 1,3-benzodioxole N-phenylpiperazine derivative with potent alpha 1A/D-Adrenergic receptor blocking properties. European Journal of Medicinal Chemistry, 2011, 46, 3000-3012.	5.5	32
69	The Role of Natural Products in the Discovery of New Drug Candidates for the Treatment of Neurodegenerative Disorders I: Parkinsons Disease. CNS and Neurological Disorders - Drug Targets, 2011, 10, 239-250.	1.4	32
70	Synthesis and analgesic profile of novel N-containing heterocycle derivatives: arylidene 3-phenyl-1,2,4-oxadiazole-5-carbohydrazide. Il Farmaco, 1999, 54, 747-757.	0.9	31
71	Adenosine A_{2A} receptor agonist prevents cardiac remodeling and dysfunction in spontaneously hypertensive male rats after myocardial infarction. Drug Design, Development and Therapy, 2017, Volume11, 553-562.	4.3	31
72	Molecular modeling of novel 1H-pyrazolo[3,4-b]pyridine derivatives designed as isosters of the antimalarial mefloquine. Computational and Theoretical Chemistry, 2002, 579, 31-39.	1.5	28

#	Article	IF	Citations
73	Studies on diastereoselective reduction of cyclic Î²-ketoesters with boron hydrides. Part 4: The reductive profile of functionalized cyclohexanone derivatives. Tetrahedron, 2004, 60, 2745-2755.	1.9	28
74	A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives. Scientific Reports, 2019, 9, 14.	3.3	28
75	Local intersection volume: a new 3D descriptor applied to develop a 3D-QSAR pharmacophore model for benzodiazepine receptor ligands. European Journal of Medicinal Chemistry, 2002, 37, 219-229.	5.5	27
76	Improved Solventâ€Free Dakin Oxidation Protocol. Synthetic Communications, 2008, 38, 784-788.	2.1	27
77	Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension. Frontiers in Pharmacology, 2017, 8, 858.	3.5	27
78	New optimized piperamide analogues with potent in vivo hypotensive properties. European Journal of Pharmaceutical Sciences, 2004, 23, 363-369.	4.0	26
79	Synthesis, Biological Evaluation, and Structureâ€“activity Relationship of Clonazepam, Meclonazepam, and 1,4â€Benzodiazepine Compounds with Schistosomicidal Activity. Chemical Biology and Drug Design, 2012, 79, 943-949.	3.2	26
80	New insights into pharmacological profile of LASSBio-579, a multi-target N-phenylpiperazine derivative active on animal models of schizophrenia. Behavioural Brain Research, 2013, 237, 86-95.	2.2	26
81	Produtos naturais como candidatos a fÃ¡rmacos Ãºteis no tratamento do Mal de Alzheimer. Quimica Nova, 2004, 27, 655-660.	0.3	26
82	Expeditious, stereocontrolled syntheses of racemic and natural brasilenol through intramolecular asymmetry transfer. Absolute stereochemistry of brasilenol. Journal of Organic Chemistry, 1987, 52, 1169-1170.	3.2	25
83	Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A2 synthesis inhibition. European Journal of Pharmacology, 2010, 638, 5-12.	3.5	25
84	Can LASSBio 596 and dexamethasone treat acute lung and liver inflammation induced by microcystin-LR?. Toxicon, 2010, 56, 604-612.	1.6	25
85	Synthesis and pharmacological evaluation of new N-phenylpiperazine derivatives designed as homologues of the antipsychotic lead compound LASSBio-579. European Journal of Medicinal Chemistry, 2013, 66, 122-134.	5.5	25
86	Novel phthalimide derivatives, designed as leukotriene D4 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 1533-1535.	2.2	24
87	Constituintes quÃmicos das flores de Pterogyne nitens (Caesalpinioideae). Quimica Nova, 2008, 31, 802-806.	0.3	24
88	Synthesis and analgesic profile of conformationally constrained N-acylhydrazone analogues: Discovery of novel N-arylideneamino quinazolin-4(3H)-one compounds derived from natural safrole. Bioorganic and Medicinal Chemistry, 2009, 17, 6517-6525.	3.0	24
89	Synthesis and pharmacological evaluation of new flosulide analogues, synthesized from natural safrole. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 183-188.	2.2	23
90	Synthesis and biological evaluation of new imidazo[1,2-a]pyridine derivatives designed as mefloquine analogues. Il Farmaco, 2002, 57, 825-832.	0.9	23

#	Article	IF	Citations
91	Antinociceptive Profile of (-)-Spectaline: A Piperidine Alkaloid fromCassia leptophylla. Planta Medica, 2003, 69, 795-799.	1.3	23
92	New potent 5-nitrofuryl derivatives asÂinhibitors ofÂTrypanosomaÂcruzi growth. 3D-QSAR (CoMFA) studies. European Journal of Medicinal Chemistry, 2006, 41, 457-466.	5.5	23
93	Antinociceptive Profile of 2,3,6-Trisubstituted Piperidine Alkaloids: 3-O-Acetyl-spectaline and Semi-synthetic Derivatives of (-)-Spectaline. Chemical and Pharmaceutical Bulletin, 2008, 56, 407-412.	1.3	23
94	Combination of docking, molecular dynamics and quantum mechanical calculations for metabolism prediction of 3,4-methylenedioxybenzoyl-2-thienylhydrazone. Journal of Molecular Modeling, 2012, 18, 2065-2078.	1.8	23
95	Studies Toward the Diastereoselective Reduction of 2-Alkoxycarbonyl-2-allyl-cyclopentanone Derivatives with Boron Hydrides. Synthetic Communications, 1995, 25, 1133-1144.	2.1	22
96	Synthesis and pharmacological evaluation of novel antinociceptive N-substituted-phenylimidazolyl-4-acylhydrazone derivatives. Il Farmaco, 2002, 57, 999-1007.	0.9	22
97	Structure-based design and biological profile of (E)-N-(4-Nitrobenzylidene)-2-naphthohydrazide, a novel small molecule inhibitor of IIºB kinase-Î². European Journal of Medicinal Chemistry, 2011, 46, 1245-1253.	5.5	22
98	The total synthesis of calcium atorvastatin. Organic and Biomolecular Chemistry, 2016, 14, 2291-2296.	2.8	22
99	Discovery of naphthylâ€‹Nâ€acylhydrazone p38Î± MAPK inhibitors with in vivo antiâ€inflammatory and antiâ€TNFâ€Î± activity. Chemical Biology and Drug Design, 2018, 91, 391-397.	3.2	22
100	Discovery of Novel Orally Active Anti-Inflammatory N-Phenylpyrazolyl-N-Glycinyl-Hydrazone Derivatives That Inhibit TNF-Î± Production. PLoS ONE, 2012, 7, e46925.	2.5	21
101	The Synthesis and Anti-inflammatory Properties of a New Sulindac Analogue Synthesized from Natural Safrole. Journal of Pharmaceutical Sciences, 1992, 81, 1219-1222.	3.3	20
102	LASSBio 596 per os avoids pulmonary and hepatic inflammation induced by microcystin-LR. Toxicon, 2011, 58, 195-201.	1.6	20
103	New Pyrazolylhydrazone Derivatives as Inhibitors of Platelet Aggregation. Journal of Pharmacy and Pharmacology, 2011, 45, 646-649.	2.4	20
104	Design, Synthesis, Antinociceptive and Anti-Inflammatory Activities of Novel Piroxicam Analogues. Molecules, 2012, 17, 14126-14145.	3.8	20
105	LASSBio-468: a new achiral thalidomide analogue which modulates TNF-Î± and NO production and inhibits endotoxic shock and arthritis in an animal model. International Immunopharmacology, 2005, 5, 485-494.	3.8	19
106	Sedation and antinociception induced by a new pyrazolo[3,4-b]pyrrolo[3,4-d]pyridine derivative (LASSBio-873) is modulated by activation of muscarinic receptors. Pharmacology Biochemistry and Behavior, 2009, 94, 70-74.	2.9	19
107	Antimicrobial activity of Pterogyne nitens Tul., Fabaceae, against opportunistic fungi. Revista Brasileira De Farmacognosia, 2010, 20, 706-711.	1.4	19
108	Pharmacological Characterization of (3-Thienylidene)-3,4-Methylenedioxybenzoylhydrazide: A Novel Muscarinic Agonist With Antihypertensive Profile. American Journal of Hypertension, 2010, 23, 135-141.	2.0	19

#	Article	IF	Citations
109	Reduction of 2-Alkyl-2-carbomethoxy-cyclopentanone Derivatives with Sodium Borohydride. II. The Elucidation of the Diastereoselective Control^a. Synthetic Communications, 1997, 27, 3241-3257.	2.1	18
110	Modelagem Molecular: Uma Ferramenta para o Planejamento Racional de FÃ¡rmacos em QuÃmica Medicinal. Quimica Nova, 1997, 20, 300-310.	0.3	18
111	MAOS and Medicinal Chemistry: Some Important Examples from the Last Years. Molecules, 2011, 16, 9274-9297.	3.8	18
112	Therapeutic effects of LASSBio-596 in an elastase-induced mouse model of emphysema. Frontiers in Physiology, 2015, 6, 267.	2.8	18
113	Design, synthesis and inÂvitro trypanocidal and leishmanicidal activities of novel semicarbazone derivatives. European Journal of Medicinal Chemistry, 2015, 100, 24-33.	5.5	18
114	Treatment with Adenosine Receptor Agonist Ameliorates Pain Induced by Acute and Chronic Inflammation. Journal of Pharmacology and Experimental Therapeutics, 2016, 358, 315-323.	2.5	18
115	Enantiofacial selective reduction of 2-allyl-2-carboethoxy-cyclopentanone mediated by baker's yeast. , 1996, 8, 305-310.		17
116	Chemo-selective hydrolysis of the iminic moiety in salicylaldehyde semicarbazone promoted by ruthenium. Inorganica Chimica Acta, 2005, 358, 3065-3074.	2.4	17
117	Synthesis and pharmacological evaluation of N-phenyl-acetamide sulfonamides designed as novel non-hepatotoxic analgesic candidates. European Journal of Medicinal Chemistry, 2009, 44, 3612-3620.	5.5	17
118	The synthesis of a new benzothiazine derivative, related to oxicams, synthesized from natural safrole. Journal of Heterocyclic Chemistry, 1992, 29, 1667-1669.	2.6	16
119	Synthesis and antiplatelet evaluation of novel aryl-sulfonamide derivatives, from natural safrole. Pharmaceutica Acta Helvetiae, 1999, 73, 281-292.	1.2	16
120	Design, synthesis and pharmacological evaluation of novel pyrazolo[3,4-b]thieno[2,3-d]pyridine acid derivatives: a new class of anti-inflammatory and anti-platelet agents. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 9-12.	2.2	16
121	Development of new CoMFA and CoMSIA 3D-QSAR models for anti-inflammatory phthalimide-containing TNFÎ± modulators. Bioorganic and Medicinal Chemistry, 2006, 14, 6874-6885.	3.0	16
122	Novel Potent Imidazo[1,2-a]pyridine-N-Glycinyl-Hydrazone Inhibitors of TNF-Î± Production: In Vitro and In Vivo Studies. PLoS ONE, 2014, 9, e91660.	2.5	16
123	Identification of LASSBio-1945 as an inhibitor of SARS-CoV-2 main protease (M^{PRO}) through in silico screening supported by molecular docking and a fragment-based pharmacophore model. RSC Medicinal Chemistry, 2021, 12, 110-119.	3.9	16
124	Molecular docking study and development of an empirical binding free energy model for phosphodiesterase 4 inhibitors. Bioorganic and Medicinal Chemistry, 2006, 14, 6001-6011.	3.0	15
125	Anti-atherogenic Effects of a New Thienylacylhydrazone Derivative, LASSBio-788, in Rats Fed a Hypercholesterolemic Diet. Journal of Pharmacological Sciences, 2013, 123, 47-57.	2.5	15
126	Serotonergic neurotransmission mediates hypothermia induced by the N-phenylpiperazine antipsychotic prototypes LASSBio-579 and LASSBio-581. Pharmacology Biochemistry and Behavior, 2008, 89, 23-30.	2.9	14

#	Article	IF	Citations
127	Structure-based prediction and biosynthesis of the major mammalian metabolite of the cardioactive prototype LASSBio-294. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3734-3736.	2.2	14
128	Anti-inflammatory effects of LASSBio-998, a new drug candidate designed to be a p38 MAPK inhibitor, in an experimental model of acute lung inflammation. Pharmacological Reports, 2011, 63, 1029-1039.	3.3	14
129	Docking, Synthesis and Anti-Diabetic Activity of Novel Sulfonylhydrazone Derivatives Designed as PPAR-Gamma Agonists. Current Topics in Medicinal Chemistry, 2012, 12, 2037-2048.	2.1	14
130	Docking, synthesis and pharmacological activity of novel urea-derivatives designed as p38 MAPK inhibitors. European Journal of Medicinal Chemistry, 2012, 54, 264-271.	5.5	14
131	Biotransformation of LASSBio-579 and pharmacological evaluation of p -hydroxylated metabolite a N -phenylpiperazine antipsychotic lead compound. European Journal of Medicinal Chemistry, 2013, 62, 214-221.	5.5	14
132	A novel CaÂ²+ channel antagonist reverses cardiac hypertrophy and pulmonary arteriolar remodeling in experimental pulmonary hypertension. European Journal of Pharmacology, 2013, 702, 316-322.	3.5	14
133	Gastroprotective effects of N-acylarylhydrazone derivatives on ethanol-induced gastric lesions in mice are dependent on the NO/cGMP/KATP pathway. Biochemical Pharmacology, 2019, 169, 113629.	4.4	14
134	Bioisosteric Replacement of Arylamide-Linked Spine Residues with N-Acylhydrazones and Selenophenes as a Design Strategy to Novel Dibenzosuberone Derivatives as Type I 1/2 p38Î± MAP Kinase Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 7347-7354.	6.4	14
135	Selective synthesis of brasilenol, a novel sesquiterpene from the sea hare Aplysia brasiliana and the red alga Laurencia obtusa. Journal of Organic Chemistry, 1986, 51, 4250-4253.	3.2	13
136	Electrospray ionization mass and tandem mass spectra of a series ofN-pyrazolylmethyl andN-triazolylmethylN-phenylpiperazines: new dopaminergic ligands with potential antipsychotic properties. Journal of Mass Spectrometry, 2005, 40, 815-820.	1.6	13
137	The molecular basis for coxib inhibition of p38Î± MAP kinase. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3506-3509.	2.2	13
138	Structural insights into IKKÎ² inhibition by natural products staurosporine and quercetin. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6907-6910.	2.2	13
139	Therapeutic approaches for tumor necrosis factor inhibition. Brazilian Journal of Pharmaceutical Sciences, 2011, 47, 427-446.	1.2	13
140	LASSBio-1135: A Dual TRPV1 Antagonist and Anti-TNF-Alpha Compound Orally Effective in Models of Inflammatory and Neuropathic Pain. PLoS ONE, 2014, 9, e99510.	2.5	13
141	Recent Advances in Development of Polyphenols as Anticancer Agents. Mini-Reviews in Medicinal Chemistry, 2018, 18, 1265-1269.	2.4	13
142	Highly diastereoselective mercury-mediated synthesis of functionalized 2-azabicyclo[3.3.0]octane derivatives. Tetrahedron Letters, 2002, 43, 1607-1611.	1.4	12
143	Characterization of the conformational ensemble from bioactive N-acylhydrazone derivatives. Journal of Molecular Graphics and Modelling, 2010, 28, 446-454.	2.4	12
144	Potential Inhibitory Effect of LASSBio-596, a New Thalidomide Hybrid, on Inflammatory Corneal Angiogenesis in Rabbits. Ophthalmic Research, 2012, 48, 177-185.	1.9	12

#	Article	IF	Citations
145	Structure Re-determination of LASSBio-294 â€“ a cardioactive compound of the N-acylhydrazone class â€“ using X-ray powder diffraction data. Powder Diffraction, 2013, 28, S491-S509.	0.2	12
146	Design, synthesis, characterization, cytotoxic and structure activity relationships of novel Ru(II) complexes. Chinese Chemical Letters, 2015, 26, 721-726.	9.0	12
147	Synthesis, solubility, plasma stability, and pharmacological evaluation of novel sulfonylhydrazones designed as anti-diabetic agents. Drug Design, Development and Therapy, 2016, Volume 10, 2869-2879.	4.3	12
148	The novel piperazine-containing compound LQFM018: Necroptosis cell death mechanisms, dopamine D4 receptor binding and toxicological assessment. Biomedicine and Pharmacotherapy, 2018, 102, 481-493.	5.6	12
149	Design and Synthesis of a New 4-Oxa-8.OMEGA.-11-deoxy-5,6-dihydroprostacyclin Analogue.. Chemical and Pharmaceutical Bulletin, 1996, 44, 2157-2161.	1.3	11
150	O-Alkylation of Bioactive Phthalimide Derivatives Under Microwave Irradiation in Dry Media. Synthetic Communications, 2000, 30, 3291-3306.	2.1	11
151	Chiral separation of Î³-butyrolactone derivatives by gas chromatography on 2,3-di-O-methyl-6-O-tert.-butyldimethylsilyl-Î²-cyclodextrin. Journal of Chromatography A, 2003, 985, 321-331.	3.7	11
152	Vasodilatory activity and antihypertensive profile mediated by inhibition of phosphodiesterase type 1 induced by a novel sulfonamide compound. Fundamental and Clinical Pharmacology, 2012, 26, 690-700.	1.9	11
153	Investigating the therapeutic effects of LASSBio-596 in an inÂvivo model of cylindrospermopsin-induced lung injury. Toxicon, 2015, 94, 29-35.	1.6	11
154	Improvement of enantioselective syntheses and chiral high resolution gas chromatographic analyses of (+)-2-allyl-2-carboethoxy-cyclopentanol. , 1997, 9, 321-324.		10
155	Synthesis of Piperamides and New Analogues from Natural Safrole. Synthetic Communications, 1999, 29, 263-273.	2.1	10
156	SYNTHESIS OF NATURAL AMIDE ALKALOID PIPERDARDINE AND A NEW BIOACTIVE ANALOGUEâ€. Synthetic Communications, 2001, 31, 117-123.	2.1	10
157	STUDIES ON THE DIASTEREO- SELECTIVE REDUCTION OF 2-ACETYL-2-ALKYL- Î³-BUTYROLACTONES WITH BORON HYDRIDES*. Synthetic Communications, 2002, 32, 505-526.	2.1	10
158	Thienylhydrazone derivative increases sarcoplasmic reticulum Ca2+ release in mammalian skeletal muscle. European Journal of Pharmacology, 2003, 470, 79-85.	3.5	10
159	Novas estratÃ©gias terapÃªuticas para o tratamento da depressÃ£o: uma visÃ£o da quÃmica medicinal. Quimica Nova, 2003, 26, 347-358.	0.3	10
160	Synthesis, pharmacological evaluation and docking studies of new sulindac analogues. European Journal of Medicinal Chemistry, 2009, 44, 1959-1971.	5.5	10
161	3-Aminothiophene-2-Acylhydrazones: Non-Toxic, Analgesic and Anti-Inflammatory Lead-Candidates. Molecules, 2014, 19, 8456-8471.	3.8	10
162	N-acylhydrazone improves exercise intolerance in rats submitted to myocardial infarction by the recovery of calcium homeostasis in skeletal muscle. Life Sciences, 2014, 94, 30-36.	4.3	10

#	Article	IF	Citations
163	Structural characterization of LASSBio-1289: a new vasoactive N-methyl-N-acylhydrazone derivative. CrystEngComm, 2015, 17, 165-173.	2.6	10
164	Respiratory and Systemic Effects of LASSBio596 Plus Surfactant in Experimental Acute Respiratory Distress Syndrome. Cellular Physiology and Biochemistry, 2016, 38, 821-835.	1.6	10
165	Structural characterization and cytotoxicity studies of different forms of a combretastatin A4 analogue. Journal of Molecular Structure, 2017, 1147, 226-234.	3.6	10
166	Synthesis, Pharmacological Profile and Docking Studies of New Sulfonamides Designed as Phosphodiesterase-4 Inhibitors. PLoS ONE, 2016, 11, e0162895.	2.5	10
167	Chemical Intuition in Drug Design and Discovery. Current Topics in Medicinal Chemistry, 2019, 19, 1679-1693.	2.1	10
168	Synthesis of pyrazole derivatives as potential bioisosteres of thromboxaneâ€synthetase inhibitors. Journal of Heterocyclic Chemistry, 1992, 29, 407-411.	2.6	9
169	The synthesis and analgesic properties of new spiroisochromanyl acid derivatives synthesized from natural safrole. Journal of Heterocyclic Chemistry, 1995, 32, 959-962.	2.6	9
170	New antithrombotic aryl-sulfonylthiosemicarbazide derivatives synthesized from natural safrole. Journal of the Brazilian Chemical Society, 1999, 10, 421-428.	0.6	9
171	Enzymatic hydrolysis by immobilized lipase applied to a new prototype anti-asthma drug. Biochemical Engineering Journal, 2004, 21, 103-110.	3.6	9
172	Benzenesulfonamide attenuates monocrotaline-induced pulmonary arterial hypertension in a rat model. European Journal of Pharmacology, 2012, 690, 176-182.	3.5	9
173	Synthesis and Pharmacological Evaluation of Novel Phenyl Sulfonamide Derivatives Designed as Modulators of Pulmonary Inflammatory Response. Molecules, 2012, 17, 14651-14672.	3.8	9
174	Antinociceptive effects of an extract, fraction and an isolated compound of the stem bark of Maytenus rigida. Revista Brasileira De Farmacognosia, 2012, 22, 598-603.	1.4	9
175	LASSBio-1425, an analog of thalidomide, decreases triglyceride and increases HDL cholesterol levels by inhibition of TNF-Î± production. International Journal of Cardiology, 2016, 202, 497-499.	1.7	9
176	The Synthesis and Antiinflammatory Activity of 1-Alkyl-Isochroman-1-yl Acetic Acids Derivatives. Journal of the Brazilian Chemical Society, 1993, 4, 40-44.	0.6	9
177	Synthesis of condensed tricyclic pyrazolo[3,4-b]thieno[2,3-d]pyridine and related isostere derivatives. Journal of Heterocyclic Chemistry, 1996, 33, 309-313.	2.6	8
178	A semiempirical study of pyrazole acylhydrazones as potential antimalarial agents. International Journal of Quantum Chemistry, 1996, 60, 1835-1843.	2.0	8
179	The synthesis of new isochromanylacetylarylhydrazones designed as probable non-addictive analgesic agents. Journal of the Brazilian Chemical Society, 1997, 8, 471-478.	0.6	8
180	Synthesis and pharmacological evaluation of a new class of bicyclic phospholipids, designed as platelet activating factor antagonists. Il Farmaco, 1998, 53, 327-336.	0.9	8

#	Article	IF	Citations
181	Studies on Diastereoselective Synthesis of 3-Vinyl-5-carbomethoxy-2-oxabicyclo[3.3.0]octane Derivatives Employing Palladium(II) Oxidative Cyclization. Heterocycles, 1998, 48, 2621.	0.7	8
182	Synthesis of Functionalized Î³-Spirolactone and 2-Oxabicyclo[3.3.0]octane Derivatives from Nucleophilic Oxirane Ring Opening. Tetrahedron, 2000, 56, 5289-5295.	1.9	8
183	Anti-inflammatory Profile of N-Phenylpyrazole Arylhydrazone Derivatives in Rats. Journal of Pharmacy and Pharmacology, 2010, 51, 703-707.	2.4	8
184	Antihyperalgesic effects of a novel muscarinic agonist (<scp>LASSB</scp>ioâ€873) in spinal nerve ligation in rats. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 404-411.	1.9	8
185	Vasodilator and antihypertensive effects of a novel <scp>N</scp>â€acylhydrazone derivative mediated by the inhibition of <scp>L</scp>â€type Ca²⁺ channels. Fundamental and Clinical Pharmacology, 2014, 28, 29-41.	1.9	8
186	Semicarbazone derivatives as promising therapeutic alternatives in leishmaniasis. Experimental Parasitology, 2019, 201, 57-66.	1.2	8
187	Synergistic interaction between a PDE5 inhibitor (sildenafil) and a new adenosine A2A receptor agonist (LASSBio-1359) improves pulmonary hypertension in rats. PLoS ONE, 2018, 13, e0195047.	2.5	8
188	SubstÃ¢ncias enantiomericamente puras (SEP): a questÃ£o dos fÃ¡rmacos quirais. Quimica Nova, 1997, 20, 647-656.	0.3	7
189	Synthesis of new 1,2-Benzothiazin-3-one Derivatives Designed as Dual Cyclooxygenase-2 and 5-Lipooxygenase Inhibitors. Journal of the Brazilian Chemical Society, 1998, 9, 119-130.	0.6	7
190	Synthesis and pharmacological evaluation of a new 2-azabicyclo[3.3.0]octane derivative. Journal of the Brazilian Chemical Society, 2001, 12, 408.	0.6	7
191	NSAIDs revisited: Putative molecular basis of their interactions with peroxisome proliferator-activated gamma receptor (PPARÎ³). European Journal of Medicinal Chemistry, 2008, 43, 1918-1925.	5.5	7
192	Design of new dopamine D2 receptor ligands: Biosynthesis and pharmacological evaluation of the hydroxylated metabolite of LASSBio-581. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2888-2891.	2.2	7
193	CYP1A2-mediated biotransformation of cardioactive 2-thienylidene-3,4-methylenedioxybenzoylhydrazine (LASSBio-294) by rat liver microsomes and human recombinant CYP enzymes. European Journal of Medicinal Chemistry, 2011, 46, 349-355.	5.5	7
194	Determination of the cardioactive prototype LASSBio-294 and its metabolites in dog plasma by LCâ€“MS/MS: Application for a pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2011, 55, 1024-1030.	2.8	7
195	Oral Antithrombotic Effects of Acylhydrazone Derivatives. Journal of Atherosclerosis and Thrombosis, 2013, 20, 287-295.	2.0	7
196	LASSBio-579, a prototype antipsychotic drug, and clozapine are effective in novel object recognition task, a recognition memory model. Behavioural Pharmacology, 2016, 27, 339-349.	1.7	7
197	Design, Synthesis, Experimental and Theoretical Characterization of a New Multitarget 2-Thienyl-N-Acylhydrazone Derivative. Pharmaceuticals, 2018, 11, 119.	3.8	7
198	LASSBio-596 protects gastric mucosa against the development of ethanol-induced gastric lesions in mice. European Journal of Pharmacology, 2019, 863, 172662.	3.5	7

#	Article	IF	Citations
199	Synthesis and Anti-Platelet Evaluation of New Tricyclic PAF Antagonists, Designed as Structurally Related to Hetrazepine Class - Web 2086. Journal of the Brazilian Chemical Society, 1996, 7, 247-256.	0.6	7
200	The synthesis of a new 8â€azaprostanoid. Journal of Heterocyclic Chemistry, 1989, 26, 725-728.	2.6	6
201	Synthesis of New Benzylic Ethers of Oximes Derived from 1-Phenyl-pyrazole Compounds. Synthetic Communications, 1998, 28, 1299-1321.	2.1	6
202	Novel furfurylidene N-acylhydrazones derived from natural safrole: discovery of LASSBio-1215, a new potent antiplatelet prototype. Journal of Enzyme Inhibition and Medicinal Chemistry, 2012, 27, 101-109.	5.2	6
203	Molecular docking and molecular dynamic studies of semi-synthetic piperidine alkaloids as acetylcholinesterase inhibitors. Journal of the Brazilian Chemical Society, 2012, 23, 163-170.	0.6	6
204	Structural feature evolution â€“ from fluids to the solid phase â€“ and crystal morphology study of LASSBio 1601: a cyclohexyl-N-acylhydrazone derivative. RSC Advances, 2015, 5, 39889-39898.	3.6	6
205	Structural and physicochemical characterization of sulfonylhydrazone derivatives designed as hypoglycemic agents. New Journal of Chemistry, 2017, 41, 6464-6474.	2.8	6
206	Lung and liver responses to 1- and 7-day treatments with LASSBio-596 in mice subchronically intoxicated by microcystin-LR. Toxicon, 2018, 141, 1-8.	1.6	6
207	Potent immunosuppressive activity of a phosphodiesterase-4 inhibitor N-acylhydrazone in models of lipopolysaccharide-induced shock and delayed-type hypersensitivity reaction. International Immunopharmacology, 2018, 65, 108-118.	3.8	6
208	In Vitro, In Vivo and In Silico Effectiveness of LASSBio-1386, an N-Acyl Hydrazone Derivative Phosphodiesterase-4 Inhibitor, Against Leishmania amazonensis. Frontiers in Pharmacology, 2020, 11, 590544.	3.5	6
209	Synthesis and Biological Evaluation of Pyrazolo[3,4-<i>b</i>]pyridin-4-ones as a New Class of Topoisomerase II Inhibitors. Medicinal Chemistry, 2015, 11, 342-353.	1.5	6
210	Comparative chemical and biological hydrolytic stability of homologous esters and isosteres. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 718-727.	5.2	6
211	Design of new potential 5-lipoxygenase inhibitors, dual thromboxane synthase inhibitors, and thromboxane a2 receptor antagonists byAM1. International Journal of Quantum Chemistry, 1995, 56, 181-190.	2.0	5
212	Molecular modeling on platelet-activating factor (PAF) and new proposed PAF antagonists. International Journal of Quantum Chemistry, 1996, 60, 1069-1080.	2.0	5
213	Studies on antiplatelet agents from natural safrole. Pharmaceutica Acta Helvetiae, 1999, 74, 19-28.	1.2	5
214	Chiral Gas Chromatographic Separation of 2-Oxabicyclo[3.3.0]octane Derivatives and Their Synthetic Precursors. Analytical Chemistry, 2000, 72, 3056-3062.	6.5	5
215	Esquizofrenia: quarenta anos da hipÃ³tese dopaminÃ©rgica sob a Ã³tica da QuÃmica Medicinal. Quimica Nova, 2004, 27, 447-455.	0.3	5
216	Hydrolysis of New Phthalimide-Derived Esters Catalyzed by Immobilized Lipase. Applied Biochemistry and Biotechnology, 2005, 121, 0117-0128.	2.9	5

#	Article	IF	Citations
217	Um paradigma da quÃmica medicinal: a flexibilidade dos ligantes e receptores. Quimica Nova, 2005, 28, 95-102.	0.3	5
218	Thalidomide and Analogs as Anti-Inflammatory and Immunomodulator Drug Candidates. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2006, 5, 79-95.	1.1	5
219	LASSBio-1586, an N-acylhydrazone derivative, attenuates nociceptive behavior and the inflammatory response in mice. PLoS ONE, 2018, 13, e0199009.	2.5	5
220	What is hidden in the biodiversity? The role of natural products and medicinal chemistry in the drug discovery process. Anais Da Academia Brasileira De Ciencias, 2019, 91, e20190306.	0.8	5
221	Reduction of cardiac and renal dysfunction by new inhibitor of DPP4 in diabetic rats. Pharmacological Reports, 2019, 71, 1190-1200.	3.3	5
222	AplicaÃ§Ã£o de anÃ¡lise de componentes principais para verificaÃ§Ã£o de atribuiÃ§Ãµes de sinais nos espetros de RMN Â¹H: o caso dos 3-aril (1,2,4)-oxadiazol-5-carboidrazida benzilidenos. Quimica Nova, 2005, 28, 492-496.	0.3	5
223	SÃntese de Î²-cetoÃ©steres cÃclicos: novo procedimento para ciclizaÃ§Ãµes de Dieckmann empregando ALCL3 e trietilamina. Quimica Nova, 1997, 20, 435-437.	0.3	4
224	Toward a platelet-activating factor pseudoreceptor: Semiempirical modeling of cation-Ï€ and hydrogen bond interactions in agonist binding. Computational and Theoretical Chemistry, 1998, 429, 217-227.	1.5	4
225	Electron impact mass spectrometry of some 3-[3-(4-aryl)-1,2,4-oxadiazole-5-yl] acyl arylaldehyde hydrazone derivatives. Spectroscopy, 2000, 14, 115-120.	0.8	4
226	Novel Agonist of Adenosine Receptor Induces Relaxation of Corpus Cavernosum in Guinea Pigs: An InÂVitro and InÂVivo Study. Urology, 2015, 85, 1214.e17-1214.e21.	1.0	4
227	Partial agonism and fast dissociation of LASSBio-579 at dopamine D2 receptor. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 62, 1-6.	4.8	4
228	Oxidative imbalance in mice intoxicated by microcystin-LR can be minimized. Toxicon, 2018, 144, 75-82.	1.6	4
229	Synthesis, Pharmacological Evaluation and Docking Study of a New Modulator of Microtubule Polymerization. Letters in Drug Design and Discovery, 2018, 15, 778-786.	0.7	4
230	New Benzofuran N-Acylhydrazone Reduces Cardiovascular Dysfunction in Obese Rats by Blocking TNF-Alpha Synthesis . Drug Design, Development and Therapy, 2020, Volume 14, 3337-3350.	4.3	4
231	Novel phosphatidylinositol 4-kinases III beta (PI4KIIIÎ²) inhibitors discovered by virtual screening using free energy models. Journal of Computer-Aided Molecular Design, 2020, 34, 1091-1103.	2.9	4
232	In Vitro Microsomal Hepatic Metabolism of Antiasthmatic Prototype LASSBio-448. Current Topics in Medicinal Chemistry, 2014, 14, 1388-1398.	2.1	4
233	Semiempirical calculations on the mechanism of stereoselective NaBH4 reduction of 2-methoxycarbonyl-2-allyl-cyclopentanone. Computational and Theoretical Chemistry, 1995, 340, 193-199.	1.5	3
234	The Molecular Basis of COX-2 Versus COX-1 Selectivity of Lumiracoxib by Molecular Docking Studies. Letters in Drug Design and Discovery, 2007, 4, 422-425.	0.7	3

#	Article	IF	Citations
235	Desafios da indÃºstria farmacÃªutica brasileira. Quimica Nova, 2013, 36, 1557-1560.	0.3	3
236	A combined experimental and in silico characterization to highlight additional structural features and properties of a potentially new drug. Journal of Molecular Structure, 2017, 1146, 735-743.	3.6	3
237	The antithrombotic and haemostatic effects of LASSBio-752: a synthetic, orally active compound in an arterial and venous thrombosis model in rats. Journal of Pharmacy and Pharmacology, 2017, 69, 1374-1380.	2.4	3
238	Synthesis, X-ray diffraction study and pharmacological evaluation of 3-amino-4-methylthiophene-2-acylcarbohydrazones. Anais Da Academia Brasileira De Ciencias, 2018, 90, 1073-1088.	0.8	3
239	Novel VEGFRâ€2 inhibitors with an Nâ€acylhydrazone scaffold. Archiv Der Pharmazie, 2020, 353, e2000130.	4.1	3
240	Synthesis, Aqueous Solubility, Metabolic Stability and Pharmacological Profile of Simplified Urea Derivatives. Letters in Drug Design and Discovery, 2018, 15, 766-777.	0.7	3
241	Pre-clinical evaluation of LASSBio-1491: From in vitro pharmacokinetic study to in vivo leishmanicidal activity. PLoS ONE, 2022, 17, e0269447.	2.5	3
242	A proposed molecular basis for the selective resveratrol inhibition of the PGHS-1 peroxidase activity. Bioorganic and Medicinal Chemistry, 2005, 13, 5981-5985.	3.0	2
243	Evaluating the prophylactic potential of the phtalimide derivative LASSBio 552 on allergen-evoked inflammation in rats. European Journal of Pharmacology, 2005, 511, 219-227.	3.5	2
244	Synthesis and characterization of the atropisomeric relationships of a substituted Nâ€phenylâ€bipyrazole derivative with antiâ€inflammatory properties. Chirality, 2012, 24, 463-470.	2.6	2
245	In vivo effect of LASSBio-785, a lipid-lowering and anti-inflammatory agent, on cardiac Ca2+-ATPases from hypercholesterolemic rats. International Journal of Cardiology, 2015, 201, 282-284.	1.7	2
246	Evaluation of Functional Selectivity of Haloperidol, Clozapine, and LASSBio-579, an Experimental Compound With Antipsychotic-Like Actions in Rodents, at G Protein and Arrestin Signaling Downstream of the Dopamine D2 Receptor. Frontiers in Pharmacology, 2019, 10, 628.	3.5	2
247	Carbamoyl-N-aryl-imine-urea: a new framework to obtain a putative leishmanicidal drug-candidate. RSC Advances, 2020, 10, 12384-12394.	3.6	2
248	Structural Characteristics of Protein Kinases and Their Inhibitors in Clinical Use. Revista Virtual De Quimica, 2018, 10, 1280-1303.	0.4	2
249	Medicinal Chemistry and the paradigm of the lead compound. Revista Virtual De Quimica, 2009, 1, .	0.4	2
250	Spectaline, cassine and semi-synthetic analogues as potential candidate drugs for the treatment of Alzheimer disease. Revista Virtual De Quimica, 2010, 2, .	0.4	2
251	The Bench of Science. Revista Virtual De Quimica, 2018, 10, 1-1.	0.4	2
252	Crystal structure of pyrazole derivatives. IV. 5-chloro-4-chlorosulfonyl-3-methyl-1-phenylpyrazole. Journal of Chemical Crystallography, 1996, 26, 759-762.	1.1	1

#	Article	IF	Citations
253	Proposal of a new PAF pharmacophoric map by the AM1 method. European Journal of Pharmaceutical Sciences, 1999, 8, 309-315.	4.0	1
254	Agentes antiasmÃ¡ticos modernos: antagonistas de receptores de leucotrienos cisteÃ¯nicos. Quimica Nova, 2002, 25, 825-834.	0.3	1
255	High performance liquid chromatography method for quantification of the N-phenylpiperazine derivative LASSBio-579 in rat plasma. Quimica Nova, 2007, 30, 1919-1922.	0.3	1
256	Cardiovascular Effects of a Novel Synthetic Analogue of Naturally Occurring Piperamides. Journal of Cardiovascular Pharmacology, 2010, 56, 293-299.	1.9	1
257	Design, synthesis, structural characterization and in vitro cytotoxic activity of mononuclear Ru(II)complexes. Medicinal Chemistry Research, 2016, 25, 2127-2132.	2.4	1
258	LASSBio-596: Of the discovery to the pre-clinical studies. Revista Virtual De Quimica, 2010, 2, .	0.4	1
259	Editorial - fÃ¡rmacos genÃ©ricos: importÃ¡-los atÃ© quando?. Journal of the Brazilian Chemical Society, 2010, 21, 775-775.	0.6	1
260	Opportunities and Challenges for Innovation in Pharmaceuticals: Now or Never!. Revista Virtual De Quimica, 2013, 5, .	0.4	1
261	SYNTHESIS OF NEW ISOSTERIC HETEROTRICYCLIC DERIVATIVES: PYRAZOLO[3,4-b]THIENO[3,2-e]PYRIDINE, PYRAZOLO[3,4-b]PYRROLO[3,2-e]PYRIDINE AND FURO[2,3-b]PYRAZOLO[4,3-e]PYRIDINE. Heterocyclic Communications, 1999, 5, .	1.2	0
262	Synthesis and Biological Evaluation of New Imidazo[1,2-a]pyridine Derivatives Designed as Mefloquine Analogues.. ChemInform, 2003, 34, no.	0.0	0
263	Synthesis and Pharmacological Evaluation of Novel Antinociceptive N-Substituted-phenylimidazolyl-4-acylhydrazone Derivatives.. ChemInform, 2003, 34, no.	0.0	0
264	1-Methyl-7-(4-nitrophenyl)-3-phenylpyrazolo[3,4-b]pyrrolo[3,4-d]pyridine-6,8(3H,7H)-dione. Acta Crystallographica Section E: Structure Reports Online, 2008, 64, o2356-o2356.	0.2	0
265	Respiratory And Systemic Effects Of LASSBio596 Associated Or Not With Surfactant In An Experimental Model Of Sepsis-induced Acute Lung Injury. , 2010, , .		0
266	Cardiovascular effects induced by N-(4'-dihydro)-piperoylthiomorpholine in normotensive rats. Journal of Pharmacy and Pharmacology, 2010, 62, 1794-1800.	2.4	0
267	LASSBio-542: Novel Thalidomide Analog Distinctly Modulates IL-10 and Inhibits Angiogenesis. Current Bioactive Compounds, 2012, 8, 167-175.	0.5	0
268	Case Study on Receptor Tyrosine Kinases EGFR, VEGFR, and PDGFR. Topics in Medicinal Chemistry, 2020, , 155-201.	0.8	0
269	Design and Synthesis In Silico Drug-like Prediction and Pharmacological Evaluation of Cyclopolymethylenic Homologous of LASSBio-1514. Molecules, 2021, 26, 4828.	3.8	0
270	LASSBio-596: a New Pre-clinical Candidate for Rheumatoid Arthritis?. Inflammation, 2022, 45, 528-543.	3.8	0

#	Article	IF	Citations
271	Title is missing!. Quimica Nova, 2000, 23, 719-719.	0.3	0
272	Discovery of novel heteroarylazoleN-phenylpiperazine prototypes candidates to atypic antipsychotic drugs. Revista Virtual De Quimica, 2010, 2, .	0.4	0
273	ESPECIAL DEDICADO AO INCT-INOFAR. Revista Virtual De Quimica, 2010, 2, .	0.4	0
274	A Theoretical Investigation on the Pleiotropic Effects of Statins as p38 MAP Kinase Ligands. Letters in Drug Design and Discovery, 2010, 7, 546-550.	0.7	0
275	Pharmaceutical sciences scenario in CNPq research fellowship. Brazilian Journal of Pharmaceutical Sciences, 2013, 49, V-VI.	1.2	0
276	Resposta Ã CiÃªncia AmeaÃ§ada. Revista Virtual De Quimica, 2017, 9, 1393-1393.	0.4	0
277	Hydrolysis of New Phthalimide-Derived Esters Catalyzed by Immobilized Lipase. , 2005, , 117-128.		0
278	Effect of Sâ€“Se Bioisosteric Exchange on Affinity and Intrinsic Efficacy of Novel N-acylhydrazone Derivatives at the Adenosine A2A Receptor. Molecules, 2021, 26, 7364.	3.8	0